Literature DB >> 21366405

Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients.

Lifeng Liu1, Jing Xie, Jianpin Sun, Yang Han, Chao Zhang, Hongwei Fan, Zhengyin Liu, Zhifeng Qiu, Yuxian He, Taisheng Li.   

Abstract

BACKGROUND: Immunological memory is the basis for vaccination. Currently, the longitudinal profiles of antibody responses in recovered severe acute respiratory syndrome (SARS) patients have not been fully characterized.
METHODS: In this study we sequentially followed up 19 recovered SARS patients over a 3-y period in order to characterize the dynamic changes in antibody responses against viral components in detail. In addition, 4 blood samples were obtained at month 60.
RESULTS: We found that immunoglobulin G (IgG) antibodies and their neutralizing activities decreased throughout the entire phase of the study. For IgG antibodies in the 3rd y, the positive rate of whole-virus-specific antibodies was 42%, which was tested with commercial kits at 1/10 dilution of the sera. In comparison, the positive rate of spike (S) protein-specific antibodies was 100%, which was tested by spike protein-based ELISA at 1/100 dilution; 4 samples at month 60 were included. The average optical density (OD) reading of nucleocapsid (N) protein-specific antibodies fell dramatically between month 3 and month 12, and it decreased gradually at low levels that were a little higher than the cut-off value from month 12. For neutralizing antibodies, neutralizing activity was detectable in 89% of recovered patients in the 3rd y. S protein-specific IgG levels (r = 0.717) correlated better with neutralizing activity than SARS coronavirus-specific IgG levels (r = 0.571).
CONCLUSIONS: These systematic findings provide valuable information on natural humoral memory responses, and the data will be helpful for understanding the pathogenesis of SARS coronavirus infection and for the rational design of vaccines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21366405     DOI: 10.3109/00365548.2011.560184

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  16 in total

1.  Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy.

Authors:  Dale L Barnard; Yohichi Kumaki
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

2.  Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.

Authors:  Yang Yang; Minghui Yang; Yun Peng; Yanhua Liang; Jing Yuan; Yingxia Liu; Jinli Wei; Li Xing; Liping Guo; Xiaohe Li; Jie Li; Jun Wang; Mianhuan Li; Zhixiang Xu; Mingxia Zhang; Fuxiang Wang; Yi Shi
Journal:  Nat Microbiol       Date:  2022-02-07       Impact factor: 30.964

3.  Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.

Authors:  Tongqing Zhou; I-Ting Teng; Adam S Olia; Gabriele Cerutti; Jason Gorman; Alexandra Nazzari; Wei Shi; Yaroslav Tsybovsky; Lingshu Wang; Shuishu Wang; Baoshan Zhang; Yi Zhang; Phinikoula S Katsamba; Yuliya Petrova; Bailey B Banach; Ahmed S Fahad; Lihong Liu; Sheila N Lopez Acevedo; Bharat Madan; Matheus Olivera de Souza; Xiaoli Pan; Pengfei Wang; Jacy R Wolfe; Michael Yin; David D Ho; Emily Phung; Anthony DiPiazza; Lauren Chang; Olubukula Abiona; Kizzmekia S Corbett; Brandon J DeKosky; Barney S Graham; John R Mascola; John Misasi; Tracy Ruckwardt; Nancy J Sullivan; Lawrence Shapiro; Peter D Kwong
Journal:  SSRN       Date:  2020-07-21

4.  Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans.

Authors:  Andreas Puschnik; Louis Lau; Elizabeth A Cromwell; Angel Balmaseda; Simona Zompi; Eva Harris
Journal:  PLoS Negl Trop Dis       Date:  2013-06-13

5.  The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection.

Authors:  Yong Xia; Honghai Hong; Yao Feng; Meiling Liu; Xingfei Pan; Dexiong Chen
Journal:  Int J Infect Dis       Date:  2020-05-17       Impact factor: 3.623

Review 6.  The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection.

Authors:  Paul Kellam; Wendy Barclay
Journal:  J Gen Virol       Date:  2020-08       Impact factor: 3.891

7.  A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.

Authors:  Angkana T Huang; Bernardo Garcia-Carreras; Matt D T Hitchings; Bingyi Yang; Leah C Katzelnick; Susan M Rattigan; Brooke A Borgert; Carlos A Moreno; Benjamin D Solomon; Luke Trimmer-Smith; Veronique Etienne; Isabel Rodriguez-Barraquer; Justin Lessler; Henrik Salje; Donald S Burke; Amy Wesolowski; Derek A T Cummings
Journal:  Nat Commun       Date:  2020-09-17       Impact factor: 14.919

Review 8.  COVID-19: benefits and risks of passive immunotherapeutics.

Authors:  Ankur Gupta; Rashmi Karki; Himanshu R Dandu; Kuldeep Dhama; Madan Lb Bhatt; Shailendra K Saxena
Journal:  Hum Vaccin Immunother       Date:  2020-09-22       Impact factor: 3.452

Review 9.  The role and uses of antibodies in COVID-19 infections: a living review.

Authors:  D Oliver Scourfield; Sophie G Reed; Max Quastel; Jennifer Alderson; Valentina M T Bart; Alicia Teijeira Crespo; Ruth Jones; Ellie Pring; Felix Clemens Richter; Stephanie E A Burnell
Journal:  Oxf Open Immunol       Date:  2021-01-28

Review 10.  Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19.

Authors:  Nevio Cimolai
Journal:  SN Compr Clin Med       Date:  2020-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.